Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Shares Outstanding (Diluted Average) (2021 - 2023)

Terns Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $71.5 million for Q3 2023.

  • For Q3 2023, Shares Outstanding (Diluted Average) rose 140.49% year-over-year to $71.5 million; the TTM value through Sep 2023 reached $71.5 million, up 140.49%, while the annual FY2022 figure was $36.0 million, 58.69% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $71.5 million in Q3 2023 per TERN's latest filing, up from $70.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $71.5 million in Q3 2023 to a low of $21.8 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 3 years is $41.4 million, with a median of $29.7 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 36.17% in 2022, then surged 179.1% in 2023.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $22.7 million in 2021, then soared by 58.69% to $36.0 million in 2022, then soared by 98.51% to $71.5 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Shares Outstanding (Diluted Average) are $71.5 million (Q3 2023), $70.6 million (Q2 2023), and $69.8 million (Q1 2023).